TG Therapeutics - TGTX Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TGTX, but not buy additional shares or sell existing shares.
View TGTX analyst ratings or view top-rated stocks.

6 brokerages have issued 12-month target prices for TG Therapeutics' shares. Their TGTX share price forecasts range from $6.00 to $25.00. On average, they predict the company's stock price to reach $16.80 in the next twelve months. This suggests a possible upside of 16.4% from the stock's current price.
View analysts price targets for TGTX or view top-rated stocks among Wall Street analysts.

TG Therapeutics' stock was trading at $11.83 at the beginning of 2023. Since then, TGTX shares have increased by 22.0% and is now trading at $14.43.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our TGTX earnings forecast.

TG Therapeutics, Inc. (NASDAQ:TGTX) posted its quarterly earnings data on Thursday, November, 10th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.07. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analyst estimates of $3.37 million. TG Therapeutics had a negative trailing twelve-month return on equity of 149.86% and a negative net margin of 4,749.83%.

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

TG Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.09%), Moody Aldrich Partners LLC (0.07%), Quantum Private Wealth LLC (0.03%), Dupont Capital Management Corp (0.01%), Avaii Wealth Management LLC (0.01%) and Brookstone Capital Management (0.01%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard.
View institutional ownership trends.

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TGTX stock can currently be purchased for approximately $14.43.

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $2.10 billion and generates $6.69 million in revenue each year. The biopharmaceutical company earns $-348,100,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

The company employs 286 workers across the globe.

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.